Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring
| Autor: | Corinne Garcia-Gournay, Alexandre Theron, Christine Biron-Andreani, Jean François Schved, Isabelle Diaz-Cau, Christian Leonardi, Alexandre Ranc, Elena Santagostino, Robert Navarro, Marion Dischino, Romuald Guy |
|---|---|
| Přispěvatelé: | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Clinique Les Franciscaines (ELSAN), Clinique Le Castelet, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Haemophilia A MEDLINE haemophilia A 030204 cardiovascular system & hematology 03 medical and health sciences MESH: Antibodies Bispecific 0302 clinical medicine inhibitors medicine Coagulation (water treatment) In patient Emicizumab emicizumab MESH: Humans MESH: Middle Aged business.industry [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology Hematology MESH: Hemophilia A medicine.disease major surgery MESH: Male 3. Good health Surgery MESH: Antibodies Monoclonal Humanized business 030215 immunology |
| Zdroj: | British Journal of Haematology British Journal of Haematology, Wiley, 2020, 189 (3), pp.e100-e103. ⟨10.1111/bjh.16512⟩ |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | International audience; Patients with haemophilia and high-titre inhibitors were often denied surgery due to the high risk of perioperative bleeding. However, data on bypassing agents for the management of major orthopaedic surgery showed efficacy values between 81% and 85% for activated recombinant human factor VII (rFVIIa) (Novoseven®, Novo Nordisk, Bagsværd, Denmark) and between 81% and 91% for plasma-derived activated prothrombin complex concentrates (aPCC) (Giangrande et al., 2018). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text